Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy
Am J Kidney Dis
.
2018 Dec;72(6):906.
doi: 10.1053/j.ajkd.2018.07.013.
Epub 2018 Sep 17.
Authors
Caroline Duineveld
1
,
Nicole C A J van de Kar
2
,
Jack F M Wetzels
1
Affiliations
1
Radboud University Medical Center, Nijmegen, the Netherlands.
2
Radboud University Medical Center, Nijmegen, the Netherlands; Amalia Children's Hospital, Nijmegen, the Netherlands.
PMID:
30236630
DOI:
10.1053/j.ajkd.2018.07.013
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Glomerulonephritis, Membranoproliferative*
Humans
Kidney Diseases*
Standard of Care
Substances
Antibodies, Monoclonal, Humanized
eculizumab